(Q37004269)

17 August 2017

Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity (English)

1 reference

17 August 2017

0 references

Hassan N

1

1 reference

17 August 2017

McLellan DL

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 1980

1 reference

Journal of Neurology, Neurosurgery and Psychiatry

17 August 2017

1 reference

17 August 2017

43

1 reference

17 August 2017

12

1 reference

17 August 2017

1132-1136

1 reference

Clinical experiences with a new muscle relaxant (DS 103-282 Sandoz) (author's transl)

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=490787

PubMed Central

reference URL

Time course of clinical and physiological effects of stimulation of the cerebellar surface in patients with spasticity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=490787

PubMed Central

reference URL

The pharmacology of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole (DS 103-282), a novel myotonolytic agent

29 September 2017

1 reference

https://pubmed.ncbi.nlm.nih.gov/7217960

PubMed

reference URL

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/JNNP.43.12.1132

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

7217960

1 reference